NasdaqGS:OBSV

Stock Analysis Report

Executive Summary

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy.


Snowflake Analysis

Fair value with limited growth.

Share Price & News

How has ObsEva's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OBSV's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.5%

OBSV

3.5%

US Biotechs

2.4%

US Market


1 Year Return

-83.9%

OBSV

4.6%

US Biotechs

-10.0%

US Market

Return vs Industry: OBSV underperformed the US Biotechs industry which returned 1.9% over the past year.

Return vs Market: OBSV underperformed the US Market which returned -13.3% over the past year.


Shareholder returns

OBSVIndustryMarket
7 Day-5.5%3.5%2.4%
30 Day-34.4%-3.2%-11.0%
90 Day-36.4%-2.4%-19.4%
1 Year-83.9%-83.9%5.4%4.6%-8.1%-10.0%
3 Year-72.2%-72.2%19.3%16.3%17.3%9.6%
5 Yearn/a-4.4%-8.9%36.1%21.1%

Price Volatility Vs. Market

How volatile is ObsEva's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ObsEva undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OBSV ($2.25) is trading below our estimate of fair value ($10.08)

Significantly Below Fair Value: OBSV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OBSV is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: OBSV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OBSV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OBSV is good value based on its PB Ratio (2x) compared to the US Biotechs industry average (2.5x).


Next Steps

Future Growth

How is ObsEva forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

23.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OBSV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OBSV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OBSV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OBSV's revenue (61.4% per year) is forecast to grow faster than the US market (7% per year).

High Growth Revenue: OBSV's revenue (61.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OBSV is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has ObsEva performed over the past 5 years?

-37.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OBSV is currently unprofitable.

Growing Profit Margin: OBSV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OBSV is unprofitable, and losses have increased over the past 5 years at a rate of -37.6% per year.

Accelerating Growth: Unable to compare OBSV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OBSV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: OBSV has a negative Return on Equity (-222.22%), as it is currently unprofitable.


Next Steps

Financial Health

How is ObsEva's financial position?


Financial Position Analysis

Short Term Liabilities: OBSV's short term assets ($74.8M) exceed its short term liabilities ($19.5M).

Long Term Liabilities: OBSV's short term assets ($74.8M) exceed its long term liabilities ($35.5M).


Debt to Equity History and Analysis

Debt Level: OBSV's debt to equity ratio (50.9%) is considered high.

Reducing Debt: Insufficient data to determine if OBSV's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OBSV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OBSV has less than a year of cash runway if free cash flow continues to reduce at historical rates of -31.7% each year


Next Steps

Dividend

What is ObsEva's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OBSV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate OBSV's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OBSV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OBSV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OBSV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Ernest Loumaye (67yo)

7.42s

Tenure

US$2,725,000

Compensation

Dr. Ernest Loumaye, MD, PhD, OB/GYN Co-Founded ObsEva SA in November 2012 and has been its Chief Executive Officer since November 2012. Dr. Loumaye co-founded PregLem SA in 2006 and served as its Chief Exe ...


CEO Compensation Analysis

Compensation vs Market: Ernest's total compensation ($USD2.73M) is above average for companies of similar size in the US market ($USD622.20K).

Compensation vs Earnings: Insufficient data to compare Ernest's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Ernest Loumaye
Co-Founder7.42yrsUS$2.73m6.4% $7.0m
Timothy Adams
Chief Financial Officer3.25yrsno datano data
Jean-Pierre Gotteland
Chief Scientific Officer and Head of R&D4.58yrsno datano data
Mario Corso
Senior Director of Investor Relationsno datano datano data
Delphine Renaud
Personal Assistant to the CSO and Head of R&Dno datano datano data
Wim Souverijns
Chief Commercial Officer1.75yrsno datano data
Elizabeth Ijeoma Garner
Chief Medical Officer0.75yrno datano data

3.3yrs

Average Tenure

54yo

Average Age

Experienced Management: OBSV's management team is considered experienced (3.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ernest Loumaye
Co-Founder7.42yrsUS$2.73m6.4% $7.0m
James Healy
Independent Director6.67yrsUS$52.00kno data
Barbara Duncan
Independent Director3.33yrsUS$60.00kno data
Rafaèle Tordjman
Independent Vice-Chairpersonno dataUS$52.00kno data
Frank A. G. Verwiel
Independent Chairperson of the Board3.33yrsUS$85.00kno data
Annette Clancy
Independent Director6.42yrsUS$58.00kno data
Jacky Vonderscher
Independent Director6.5yrsUS$43.00kno data
Phillip Bennett
Member of Scientific Advisory Board6.25yrsno datano data
Ben Mol
Member of Scientific Advisory Board6.25yrsno datano data
Vassilis Tsatsaris
Member of Scientific Advisory Board6.25yrsno datano data

6.3yrs

Average Tenure

57yo

Average Age

Experienced Board: OBSV's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.7%.


Top Shareholders

Company Information

ObsEva SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ObsEva SA
  • Ticker: OBSV
  • Exchange: NasdaqGS
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$108.871m
  • Shares outstanding: 48.39m
  • Website: https://www.obseva.com

Number of Employees


Location

  • ObsEva SA
  • Chemin des Aulx, 12
  • Plan-les-Ouates
  • Geneva
  • 1228
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OBSVNasdaqGS (Nasdaq Global Select)YesCommon SharesUSUSDJan 2017
OBSV NBMV (Bolsa Mexicana de Valores)YesCommon SharesMXMXNJan 2017
OBSNSWX (SIX Swiss Exchange)YesCommon SharesCHCHFJan 2017
22DDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 2017

Biography

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/07 05:50
End of Day Share Price2020/04/06 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.